- 21 Oct 2022
- ICICIdirect Research
Lupin acquires two inhalation brandsLUPIN - 669 Change: 28.95 (4.52 %)
Lupin announced signing of an agreement to acquire all rights to two inhalation medicines, Brovana® (arformoterol tartrate) Inhalation Solution and Xopenex HFA® (levalbuterol tartrate) Inhalation Aerosol, from Sunovion Pharmaceuticals Inc. (Sunovion) for a purchase price of $75 million.
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S. and strengthens the company’s presence in the respiratory therapy area. Brovana is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Xopenex HFA is a short-acting beta2-adrenergic agonist (SABA) indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age or older with reversible obstructive airway disease. IQVIA sales for the two brands combined were approximately $60 Million (MAT August 2022).